Unicycive Therapeutics (UNCY) announced that data from the Company’s oxylanthanum carbonate, OLC, bioequivalence study in healthy volunteers was published in the peer-reviewed journal, Clinical Therapeutics. The publication, entitled, “Two-Way Randomized Crossover Study to Establish Pharmacodynamic Bioequivalence Between Oxylanthanum Carbonate and Lanthanum Carbonate” described the study that established pharmacodynamic bioequivalence of OLC to Fosrenol. In the study, OLC was well tolerated and demonstrated bioequivalence to lanthanum carbonate.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Unicycive Therapeutics price target raised to $4 from $2.50 at H.C. Wainwright
- Unicycive Therapeutics files $100M mixed securities shelf
- Unicycive Therapeutics reports Q3 EPS (13c), consensus (15c)
- Unicycive Therapeutics expects cash to fund operations into 2026
- Unicycive Therapeutics announces U.S. FDA acceptane for NDA for OLC